NanoTemper Technologies unveils Dianthus uHTS — the fastest biophysical method on the market

October 14, 2024 NanoTemper IT

Munich, Germany Oct 14, 2024 — Last week, NanoTemper Technologies introduced Dianthus uHTS, greatly increasing the throughput capabilities of their breakthrough Spectral Shift technology. Spectral Shift is valued by scientists for easy setup of immobilization-free binding affinity measurements and minimal sample requirements, and Dianthus uHTS brings this technology into an automated 1536-well plate-based format.

“With Dianthus uHTS we are launching something that our customers have asked for since we founded NanoTemper. We speed up our measurement time by a factor of 1000x — it is biophysics at the speed of light!” says Philipp Baaske, founder and CEO of NanoTemper. “I’m proud to share that our team has developed a system capable of measuring a full 1536-well plate in under 8 minutes.”

NanoTemper set out to bring the advantages of its breakthrough Spectral Shift technology to the ultra-high-throughput screening community. Marco Schade, the lead developer of Dianthus uHTS explains, “Our project team worked closely with beta testers to ensure seamless integration of the system into existing automation workflows. The result is the fastest biophysical screening method available.”

For scientists performing high-throughput screening, the same method can be used for primary screens and lead optimization, dramatically reducing assay development costs. Other advantages, like not needing prior knowledge of a drug target’s binding sites, further increase the ease-of-use and flexibility of the system.

Dianthus uHTS is the solution scientists can count on to screen large compound libraries — regardless of drug target — without the limitations imposed by other methods.

About NanoTemper Technologies

At NanoTemper, our vision is to help create a world where every disease is treatable. For us, that starts by equipping scientists with reliable biophysical tools that bring them the clarity, confidence, and momentum they need to discover and develop future therapies, even difficult ones. Because the path to a disease-free world requires courage, big thinking, and collaboration, we’ll continue to create innovative products that meet the needs of our customers as they face new and difficult challenges.

NanoTemper Announces Leadership Evolution: Philipp Baaske Transitions to Executive Chairman

NanoTemper Technologies is entering a new chapter of leadership. After 16 years as Co-CEOs, Philipp Baaske ...

Up next

NanoTemper Technologies Establishes Advisory Board to Propel Innovation and Growth

NanoTemper Technologies has established an advisory board consisting of five distinguished professionals, e...

Contact Specialist

Return to education center

NanoTemper Technologies unveils Dianthus uHTS — the fastest biophysical method on the market

Previous Article

Up next

Most recent content

This guide provides an overview of the key analytical parameters obtained with Prometheus Panta, their definitions and practical relevance for protein characterization and drug development.

When working with membrane proteins, whether you’re troubleshooting aggregation, testing new solubilization strategies, or deciding when to switch detergents read this guide for practical solutions.

Learn about Prometheus Panta C: A next-generation stability characterization platform that's helping biomanufacturers bring automation into the analytical core of their development and process control

Dr. Marius Müller of Johnson & Johnson Innovative Medicine shares insights from questions about the use of nanoDSF™ technology for ID-testing and at several late stages of biotherapeutics development.

NanoTemper Technologies announces the launch of Prometheus Panta C, a solution designed to meet the evolving needs of biopharmaceutical development—from preclinical phase to commercial manufacturing.

Expert Marius Müller, PhD, Team Lead at Johnson & Johnson Innovative Medicine, shares insights into three significant trends that have potential to reshape the biopharma and biomanufacturing industry

Learn how to enhance your lab's efficiency with Prometheus Panta, from using capillary chips for high-throughput sample loading to solutions for seamless integration in automated workflows

Marius, a biophysics expert at Johnson & Johnson Innovative Medicine, shares his insights into this rapidly evolving field of biomanufacturing.

Use this curated list of must-attend 2025 biologics conferences to plan your year. Find out when and where each conference takes place, who will be there, and what you can expect.

NanoTemper Technologies is entering a new chapter of leadership. After 16 years as Co-CEOs, Philipp Baaske and Stefan Duhr have redefined their roles to better position the company for continued growt

NanoTemper Technologies has established an advisory board consisting of five distinguished professionals, each a seasoned expert in their respective fields. This move underscores NanoTemper...

The work of pre-formulations scientists is critical to de-risk the entire development process for biologics. Read on to learn more about what to consider about your buffer components for...

Each excipient class helps stabilize biologics – from monoclonal antibodies to vaccine antigens – in different ways. Read on to learn more about some of the most important excipients for...

NanoTemper Technologies, well known for creating biophysical tools that accelerate the work of drug discovery researchers, brings their groundbreaking Spectral Shift technology to the protein...

Drug Discovery Chemistry is an annual event that focuses solely on early drug discovery, where scientists from around the world gather to showcase their research and participate in thoughtful...

Learn how it’s possible to use the Prometheus Panta to extrapolate how your low concentration sample will behave once it’s scaled up and at higher concentrations used for clinical administration.

Use this list of crowd-sourced favorites to kick-start your 2024 biologics conference plans. Find out when and where each conference takes place, who will be there, which topics are covered, and...

Attending dedicated targeted protein degradation conferences and tracks is a great way to keep up with this rapidly evolving field. Here are 8 conferences you’ll want to attend in 2024.

Antibody-drug conjugates, or ADCs, are revolutionary therapeutics that represent a growing proportion of the biologics market. They combine the targeting power of a monoclonal antibody, which is...

Developability profiles help you avoid risk by collecting many quality attributes associated with each candidate, enabling you to rank each candidate by the most optimal attributes and make a...